Author
Listed:
- Francesca Rovida
(Fondazione IRCCS Policlinico San Matteo
University of Pavia)
- Irene Cassaniti
(Fondazione IRCCS Policlinico San Matteo)
- Stefania Paolucci
(Fondazione IRCCS Policlinico San Matteo)
- Elena Percivalle
(Fondazione IRCCS Policlinico San Matteo)
- Antonella Sarasini
(Fondazione IRCCS Policlinico San Matteo)
- Antonio Piralla
(Fondazione IRCCS Policlinico San Matteo)
- Federica Giardina
(Fondazione IRCCS Policlinico San Matteo)
- Josè Camilla Sammartino
(Fondazione IRCCS Policlinico San Matteo)
- Alessandro Ferrari
(Fondazione IRCCS Policlinico San Matteo)
- Federica Bergami
(Fondazione IRCCS Policlinico San Matteo)
- Alba Muzzi
(Fondazione IRCCS Policlinico San Matteo)
- Viola Novelli
(Fondazione IRCCS Policlinico San Matteo)
- Alessandro Meloni
(Fondazione IRCCS Policlinico San Matteo
University of Pavia)
- Sara Cutti
(Fondazione IRCCS Policlinico San Matteo)
- Anna Maria Grugnetti
(Fondazione IRCCS Policlinico San Matteo)
- Giuseppina Grugnetti
(Fondazione IRCCS Policlinico San Matteo)
- Claudia Rona
(Fondazione IRCCS Policlinico San Matteo)
- Marinella Daglio
(Fondazione IRCCS Policlinico San Matteo)
- Carlo Marena
(Fondazione IRCCS Policlinico San Matteo)
- Antonio Triarico
(Fondazione IRCCS Policlinico San Matteo)
- Daniele Lilleri
(Fondazione IRCCS Policlinico San Matteo)
- Fausto Baldanti
(Fondazione IRCCS Policlinico San Matteo
University of Pavia)
Abstract
Vaccine breakthrough SARS-CoV-2 infection has been monitored in 3720 healthcare workers receiving 2 doses of BNT162b2. SARS-CoV-2 infection is detected in 33 subjects, with a 100-day cumulative incidence of 0.93%. Vaccine protection against acquisition of SARS-CoV-2 infection is 83% (95%CI: 58–93%) in the overall population and 93% (95%CI: 69-99%) in SARS-CoV-2-experienced subjects, when compared with a non-vaccinated control group from the same Institution, in which SARS-CoV-2 infection occurs in 20/346 subjects (100-day cumulative incidence: 5.78%). The infection is symptomatic in 16 (48%) vaccinated subjects vs 17 (85%) controls (p = 0.01). All analyzed patients, in whom the amount of viral RNA was sufficient for genome sequencing, results infected by the alpha variant. Antibody and T-cell responses are not reduced in subjects with breakthrough infection. Evidence of virus transmission, determined by contact tracing, is observed in two (6.1%) cases. This real-world data support the protective effect of BNT162b2 vaccine. A triple antigenic exposure, such as two-dose vaccine schedule in experienced subjects, may confer a higher protection.
Suggested Citation
Francesca Rovida & Irene Cassaniti & Stefania Paolucci & Elena Percivalle & Antonella Sarasini & Antonio Piralla & Federica Giardina & Josè Camilla Sammartino & Alessandro Ferrari & Federica Bergami &, 2021.
"SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers,"
Nature Communications, Nature, vol. 12(1), pages 1-7, December.
Handle:
RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-26154-6
DOI: 10.1038/s41467-021-26154-6
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-26154-6. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.